secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001193125-23-034348
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma Q2 net loss $5.4M; cash $10.5M; first OPMD patient enrolled
-----------------------------------------------------------------------------

- Net loss of $5.4M ($0.20/share) vs $4.8M ($0.59/share) in Q2 2022; revenue $14K.
- Cash and cash equivalents $10.5M at Dec 31, 2022, up from $4.1M at June 30, 2022.
- First patient enrolled in OPMD natural history study in Jan 2023; part of BB-301 program.
- Expects IND/CTA clearance in Q2 2023; first BB-301 dosing anticipated in Q3 2023.
- R&D expenses $3.8M, up $0.7M YoY due to toxicology and manufacturing projects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523034348/0001193125-23-034348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312523034348/d375301d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-034348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer